AM-Pharma has recruited first patients with Covid-19 infection and sepsis-associated acute kidney injury (SA-AKI) in an exploratory cohort of its phase III REVIVAL pivotal trial.
08 Jan 2021
16 Dec 2020
FSD Pharma has dosed the first patients in its phase 2a clinical trial designed to assess FSD201 (ultramicronised palmitoylethanolamide or ultramicronised PEA) for the treatment of hospitalised patients with Covid-19.
03 Dec 2020
Appili Therapeutics announced that first patient has been dosed in the phase 3 PRESECO (preventing severe Covid disease) clinical trial to assess oral Avigan tablets (favipiravir) to treat Covid-19.
01 Dec 2020
NeoImmuneTech has dosed the first patient in its phase 1 study designed to assess NT-I7 (efineptakin alfa) in adult patients with mild Covid-19.
18 Nov 2020
Cerebral Therapeutics announced that the first patient has been enrolled in a Phase 2b study of intracerebroventricular drug delivery of the anti-seizure medication CT-010 in patients with medically refractory epilepsy.
05 Nov 2020
NanOlogy enrols first patient in phase 2 trial of NanoPac for intratumoral treatment of prostate cancer
NanOlogy LLC, a clinical-stage oncology company advancing intratumoral therapy for solid tumors, has enrolled the first patient in a Phase 2 clinical trial of NanoPac (sterile nanoparticulate paclitaxel) for suspension via intratumoral injection for local prostate cancer.
02 Nov 2020
Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with lenzilumab, today announced that MedStar Washington Hospital Center in Washington, D.C. treated its first Covid-19 patient with lenzilumab.
22 Oct 2020
ImmunityBio and NantKwest have dosed the first patient in phase I clinical study of a novel Covid-19 vaccine candidate called hAd5-Covid-19.
12 Oct 2020
Rigel Pharmaceuticals has recruited the first patients in a phase 2 study designed to assess the safety of fostamatinib for the treatment of hospitalised Covid-19 patients.
09 Oct 2020
As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda, in the company’s Phase 1 NOXCOVID-1 study.